Drug repurposing study finds lonafarnib effective against RSV

A study in Nature Communications identifies lonafarnib from the ReFRAME drug-repurposing library as a potent inhibitor of the RSV fusion protein, showing promise in reducing RSV infection in vitro and in vivo.

Roundups: Recent Digital Health Hires & Board Appointments

Theralink Technologies, Inc. appoints Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer

July 1, 2023

Natural Medicine Advisory Bulletin #7: December 2023 – Psychedelic Alpha

*** December’s meeting of the full Natural Medicine Advisory Board began with a handful of administrative updates from the Program Director, Attorney General’s office, and

January 10, 2024

Lawmakers, as part of ‘lab leak’ Covid inquiry, press to bar EcoHealth from federal research funds

WASHINGTON — A House panel is pushing for a virus research group and its director to be barred from any federal funds and criminally investigated,

May 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.